Premium
AGEING, OESTROGEN, PLATELETS AND THROMBOTIC RISK
Author(s) -
Miller Virginia M,
Jayachandran Muthuvel,
Owen Whyte G
Publication year - 2007
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.2007.04685.x
Subject(s) - ageing , menopause , hormone , platelet , medicine , coagulation , endocrinology , estrogen , platelet activation , adverse effect , physiology
SUMMARY1 Adverse thrombotic cardiovascular events increase in women coincident with the onset of menopause. 2 Age past menopause may be an important variable in defining the benefit/risk of hormone treatments. 3 Few studies have examined hormonal status as a variable of ageing using a polygenomic approach of both humoral and cellular components of the coagulation system. 4 Longitudinal studies of a global set of platelet functions that define procoagulant activity (i.e. adhesion, aggregation, secretion and thrombin production) in individuals with documented hormonal status are needed to better understand how hormonal changes associated with ageing impact thrombotic risk.